公开(公告)号：US20210323956A1

公开(公告)日：2021-10-21

申请号：US17268512

申请日：2019-08-12

Applicant: Novartis AG

Inventor： Christopher ADAIR ,  Katsumasa NAKAJIMA ,  Rukundo NTAGANDA ,  Julien PAPILLON ,  Troy Douglas SMITH

IPC: C07D417/12 ,  A61K45/06

Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a BRM-mediated and/or BRG1-mediated disease or disorder: Formula (I) wherein R1 through R6 are as defined herein.

公开(公告)号：US20240270738A1

公开(公告)日：2024-08-15

申请号：US18602126

申请日：2024-03-12

Applicant: NOVARTIS AG

Inventor： Christopher ADAIR ,  Katsumasa Nakajima ,  Rukundo Ntaganda ,  Julien Papillon ,  Troy Douglas Smith

IPC: C07D417/12 ,  A61K45/06

CPC classification number: C07D417/12 ,  A61K45/06

Abstract: A method of preparing compound of Formula (1), or a pharmaceutically acceptable salt thereof,




wherein R1 through R6 are as defined herein.